Interferon-beta - CytoCure
Latest Information Update: 02 Aug 2016
At a glance
- Originator CytoCure
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon beta stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 02 Aug 2016 Preclinical trials in Malignant melanoma (Combination therapy) in USA (unspecified route)